Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IQ-AI ( (GB:IBAI) ) has shared an announcement.
Imaging Biometrics, LLC and Vivan Therapeutics have announced a strategic partnership to explore new cancer indications for gallium maltolate, a compound previously promising in glioblastoma treatment. This collaboration will utilize Vivan’s high-throughput in vivo screening platform to evaluate gallium maltolate across various tumor profiles, initially focusing on colorectal cancer and extending to other challenging cancers like pancreatic and lung. This partnership aims to identify gallium maltolate’s therapeutic potential as a single agent or in combination with existing drugs, potentially expanding its clinical applications. The collaboration also sets the stage for future joint development efforts, particularly in combination therapies, which could enhance the companies’ positions in the oncology market.
More about IQ-AI
Imaging Biometrics, LLC (IB) is a biotechnology company based in Wisconsin, specializing in quantitative imaging platforms and therapeutics aimed at enhancing the efficiency and effectiveness of clinical diagnostics and treatment. It is a wholly owned subsidiary of Imaging Biometrics Limited. Vivan Therapeutics is a precision oncology company from the UK, focusing on personalized cancer treatment recommendations using a proprietary platform developed at the Icahn School of Medicine at Mount Sinai.
Average Trading Volume: 818,580
Technical Sentiment Signal: Strong Sell
Current Market Cap: £1.54M
See more data about IBAI stock on TipRanks’ Stock Analysis page.